Effect of beta2-adrenergic agonist and resistance training on maximal oxygen uptake and muscle oxidative enzymes in men
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Standard
Effect of beta2-adrenergic agonist and resistance training on maximal oxygen uptake and muscle oxidative enzymes in men. / Lemminger, Anders Krogh; Jessen, Søren; Habib, Sajad; Onslev, Johan Dejgaard; Xu, Stella Feng Sheng; Backer, Vibeke; Bangsbo, Jens; Hostrup, Morten.
I: Scandinavian Journal of Medicine & Science in Sports, Bind 29, Nr. 12, 2019, s. 1881-1891.Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Effect of beta2-adrenergic agonist and resistance training on maximal oxygen uptake and muscle oxidative enzymes in men
AU - Lemminger, Anders Krogh
AU - Jessen, Søren
AU - Habib, Sajad
AU - Onslev, Johan Dejgaard
AU - Xu, Stella Feng Sheng
AU - Backer, Vibeke
AU - Bangsbo, Jens
AU - Hostrup, Morten
N1 - This article is protected by copyright. All rights reserved.
PY - 2019
Y1 - 2019
N2 - While beta2 -adrenoceptor stimulation has been shown to increase lean mass and to alter metabolic properties of skeletal muscle, adaptations in muscle oxidative enzymes and maximal oxygen uptake (V̇O2max) in response to beta2-adrenergic agonist treatment are inadequately explored in humans, particularly in association with resistance training. Herein we investigated beta2-adrenergic-induced changes in V̇O2max, leg and arm composition, and muscle content of oxidative enzymes in response to treatment with the selective beta2-adrenergic agonist terbutaline with and without concurrent resistance training in young men. Forty-six subjects were randomized to four weeks of lifestyle maintenance (n=23) or resistance training (n=23). Within the lifestyle maintenance and resistance training group, subjects received daily terbutaline (8·0.5 mg)(n=13) or placebo (n=10) treatment. No apparent treatment by training interactions were observed during the study period. Terbutaline increased leg and arm lean mass with the intervention, whereas no treatment differences were observed in absolute V̇O2max and incremental peak power output (iPPO). Treatment main effects were observed for V̇O2-reserve (P < .05), V̇O2max relative to body mass (P < .05), V̇O2max relative to leg lean mass (P < .01), and iPPO relative to leg lean mass, in which terbutaline had a negative effect compared to placebo. Furthermore, content of electron transport chain complex I-V decreased by 11% (P < .05) for terbutaline compared to placebo. Accordingly, chronic treatment with the selective beta2-adrenergic agonist terbutaline may negatively affect V̇O2max and iPPO in relative terms, but not in absolute.
AB - While beta2 -adrenoceptor stimulation has been shown to increase lean mass and to alter metabolic properties of skeletal muscle, adaptations in muscle oxidative enzymes and maximal oxygen uptake (V̇O2max) in response to beta2-adrenergic agonist treatment are inadequately explored in humans, particularly in association with resistance training. Herein we investigated beta2-adrenergic-induced changes in V̇O2max, leg and arm composition, and muscle content of oxidative enzymes in response to treatment with the selective beta2-adrenergic agonist terbutaline with and without concurrent resistance training in young men. Forty-six subjects were randomized to four weeks of lifestyle maintenance (n=23) or resistance training (n=23). Within the lifestyle maintenance and resistance training group, subjects received daily terbutaline (8·0.5 mg)(n=13) or placebo (n=10) treatment. No apparent treatment by training interactions were observed during the study period. Terbutaline increased leg and arm lean mass with the intervention, whereas no treatment differences were observed in absolute V̇O2max and incremental peak power output (iPPO). Treatment main effects were observed for V̇O2-reserve (P < .05), V̇O2max relative to body mass (P < .05), V̇O2max relative to leg lean mass (P < .01), and iPPO relative to leg lean mass, in which terbutaline had a negative effect compared to placebo. Furthermore, content of electron transport chain complex I-V decreased by 11% (P < .05) for terbutaline compared to placebo. Accordingly, chronic treatment with the selective beta2-adrenergic agonist terbutaline may negatively affect V̇O2max and iPPO in relative terms, but not in absolute.
KW - Faculty of Science
KW - Salbutamol
KW - Beta2-agonist
KW - Strength training
KW - Endurance
KW - Doping
KW - Performance
KW - Exercise
U2 - 10.1111/sms.13544
DO - 10.1111/sms.13544
M3 - Journal article
C2 - 31442335
VL - 29
SP - 1881
EP - 1891
JO - Scandinavian Journal of Medicine & Science in Sports
JF - Scandinavian Journal of Medicine & Science in Sports
SN - 0905-7188
IS - 12
ER -
ID: 226827024